Page 4 of Dr Reddy's Laboratories

Dr. Reddy’s aims to roll out its trade generics across cities and towns in India, including rural areas.

Dr. Reddy’s is developing the proposed tocilizumab biosimilar as both intravenous and subcutaneous formulations

In the India business, FY23 revenue from India at Rs. 48.9 billion. YoY growth of 17% was primarily attributable to…

Dr. Reddy’s Regadenoson Injection is supplied as single-dose pre-filled syringes, 0.4 mg/5 mL (0.08 mg/mL).

Treprostinil is a medication used to manage and treat pulmonary arterial hypertension (PH).

Under the agreement, Eris Lifesciences will be assigned the trademark of these brands by Dr. Reddy’s for a consideration of…

The value of the total addressable market for the pipeline and approved non-marketed products in the U.S. is approximately $3.6…

The Durezol brand and generic had U.S. sales of approximately $40 million MAT for the most recent twelve months ending in…

Meanwhile, revenues during the quarter were up by 27 per cent to Rs 6,770 crore compared to Rs 5,319.7 crore…

Earlier this week, Novartis’ heart failure drug which is a combination of sacubitril and valsartan lost its patent.

The company also informed that its rituximab biosimilar has already been approved for marketing in India and over 25 emerging…